CESK1, also known as C-terminal Src kinase homologous kinase, is a non-receptor tyrosine kinase encoded by the gene CSK homologous kinase (CHEK). This protein is a member of the C-terminal Src kinase (CSK) family and plays a significant role in the negative regulation of Src family kinases (SFKs), which are involved in various cellular processes, including proliferation, differentiation, and survival.CESK1 shares structural similarities with CSK, including the SH3, SH2, and kinase domains, which are crucial for its function. The SH3 and SH2 domains are responsible for protein-protein interactions, while the kinase domain mediates the phosphorylation of target proteins, typically on tyrosine residues. CESK1 is unique, however, in that it contains a longer C-terminal region compared to CSK, which may confer distinct regulatory properties upon the protein.
The primary function of CESK1 is to phosphorylate the C-terminal inhibitory tyrosine residue on SFKs. This phosphorylation leads to a conformational change in the SFKs, resulting in their inactivation. By controlling the activity of SFKs, CESK1 indirectly influences numerous signaling pathways that govern cellular function.Dysregulation of SFK activity can contribute to the development of cancer, and thus, CESK1, by modulating these kinases, is implicated in the suppression of oncogenic signaling. The activity of CESK1 itself is regulated by various mechanisms, including its own phosphorylation and protein-protein interactions, which modulate its localization and function within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
A Hsp90 inhibitor, could indirectly affect CCT8L2 by influencing protein folding pathways. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
Another Hsp90 inhibitor, potentially impacting protein folding and stability, relevant to CCT8L2. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $92.00 $333.00 | 13 | |
Inhibits Hsp90, potentially affecting CCT8L2 activity in protein folding. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, could indirectly affect protein turnover and folding processes involving CCT8L2. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Disrupts microtubule polymerization, potentially affecting CCT8L2-related cytoskeletal proteins. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, potentially influencing CCT8L2 activity in cytoskeletal dynamics. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Inhibits microtubule formation, potentially impacting CCT8L2's function in protein folding. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Disrupts microtubule dynamics, which may indirectly affect CCT8L2 activity. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, potentially influencing cellular processes relevant to CCT8L2. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Influences GSK-3 signaling, which could indirectly affect CCT8L2 in cellular processes. | ||||||